- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immutep Ltd (IMM)
Immutep Ltd stock price live, this page displays ASX IMM stock exchange data. View the IMM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immutep Ltd real time stock price chart below.
What Is the Immutep Ltd Stock Price Today?
The Immutep Ltd stock price today is 0.047.
What Is the Stock Symbol for Immutep Ltd?
The stock symbol for Immutep Ltd is "IMM."
What Stock Exchange Does Immutep Ltd Trade On?
Immutep Ltd is listed and trades on the Sydney stock exchange.
Is Immutep Ltd a Good Stock to Buy?
Determining whether Immutep Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMM quote. (ISIN: AU000000IMM6)
What Is the Immutep Ltd Stock Price Today?
The Immutep Ltd stock price today is 0.047.
What Is the Stock Symbol for Immutep Ltd?
The stock symbol for Immutep Ltd is "IMM."
What Stock Exchange Does Immutep Ltd Trade On?
Immutep Ltd is listed and trades on the Sydney stock exchange.
Is Immutep Ltd a Good Stock to Buy?
Determining whether Immutep Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMM quote. (ISIN: AU000000IMM6)
0.047
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.047
0.049
52 wk Range
0.028
0.470
IMM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0470.049
52 wk Range
0.0280.470
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IMM Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
0.103
Upside
+119.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 6K Immutep Ltd ADR For: 13 March- Investing.com
Prima BioMed Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 6K Immutep Ltd ADR For: 16 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
3 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.103
(+119.85% Upside)
Earnings
Latest Release
Jun 03, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare IMM to Peers and Sector
Metrics to compare | IMM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −8.8x | −0.4x | |
PEG Ratio | 0.01 | −0.01 | 0.00 | |
Price/Book | 0.7x | 2.8x | 2.6x | |
Price / LTM Sales | 8.7x | 21.3x | 3.0x | |
Upside (Analyst Target) | 45.8% | 213.8% | 51.9% | |
Fair Value Upside | Unlock | 7.4% | 7.2% | Unlock |
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Immutep (IMM) Stock Price Today?
The Immutep stock price today is 0.047 AUD.
What Stock Exchange Does Immutep Trade On?
Immutep is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Immutep?
The stock symbol for Immutep is "IMM."
What Is the Immutep Market Cap?
As of today, Immutep market cap is 69.260M AUD.
What Is Immutep's Earnings Per Share (TTM)?
The Immutep EPS (TTM) is -0.057.
When Is the Next Immutep Earnings Date?
Immutep will release its next earnings report on Sep 02, 2026.
From a Technical Analysis Perspective, Is IMM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Immutep Stock Split?
Immutep has split 3 times.
How Many Employees Does Immutep Have?
Immutep has 31 employees.
What is the current trading status of Immutep (IMM)?
As of Aug 05, 2026, Immutep (IMM) is trading at a price of 0.047 AUD, with a previous close of 0.047 AUD. The stock has fluctuated within a day range of 0.047 AUD to 0.049 AUD, while its 52-week range spans from 0.028 AUD to 0.470 AUD.
What Is Immutep (IMM) Price Target According to Analysts?
The average 12-month price target for Immutep is 0.103 AUD, with a high estimate of 0.2 AUD and a low estimate of 0.04 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +119.85% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.